The CHEMOSAT kit containing Gen 2 filters has been used to treat patients since April 2011. This registry study is designed to collect the treatment outcome in patients who receive this treatment and use experience of the CHEMOSAT Kits by healthcare professionals. The safety and efficacy data from patients treated in the commercial setting is important in updating the safety profile as well as the risk/benefit of the treatment. The resource utilization information is essential in planning treatment strategy for patients.